Reverse hybrid regimen — Competitive Intelligence Brief

Reverse hybrid regimen (Reverse hybrid regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral therapy. Area: Infectious disease.

marketed Antiretroviral therapy Infectious disease Small molecule

Target snapshot

Reverse hybrid regimen (Reverse hybrid regimen) — Ayman Magd Eldin Mohammad Sadek. Reverse hybrid regimen combines antiretroviral therapy with other treatments to suppress HIV replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reverse hybrid regimen TARGET	Reverse hybrid regimen	Ayman Magd Eldin Mohammad Sadek	marketed	Antiretroviral therapy
Rapidly Cycled HAART	Rapidly Cycled HAART	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Antiretroviral therapy regimen (combination therapy)
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Optimized background ARV	Optimized background ARV	Hoffmann-La Roche	marketed	Antiretroviral therapy combination
Background ARVs	Background ARVs	Hoffmann-La Roche	marketed	Antiretroviral therapy (combination regimen)
Other ART regimens	Other ART regimens	Juan A. Arnaiz	phase 3	Antiretroviral therapy combination regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral therapy class)

1. Ayman Magd Eldin Mohammad Sadek · 1 drug in this class